Sinopharm Group

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

Retrieved on: 
Monday, October 2, 2023
Volunteering, Instituto Butantan, University, School of Public Health, COVID-19, Infection, ATV, Chinese Academy of Medical Sciences COVID-19 vaccine, Research, TVT, SPB, Chinese Academy of Engineering, Science, BFC, University of Hong Kong, Public health, Sinopharm (company), School, Mass vaccination, RED, III, United Arab Emirates, Safety, Sinopharm Group, Vaccine, Sinovac Biotech, SEA

BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax. Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.

Key Points: 
  • BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax.
  • Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.
  • The film also reveals the story of how clinical phase III of China's vaccine has been conducted in Brazil.
  • The second half of the film documents China's calls for the world to work together to face down public safety incidents together.

China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Administration, Vaccination, Meningitis, Attenuated vaccine, Meningococcal disease, Rabies, MPSV4, Conjugate vaccine, Safety, Sinovac Biotech, PCV13, Expanded Program on Immunization, Infant, EPI, Sinopharm Group, Birth rate, Category, Parent, Pneumococcal polysaccharide vaccine, Forecasting, Policy, DTP, COVID-19, Category 2, R, Ageing, Pharmaceutical industry, Vaccine, Haemophilus, Immunization

As a result, China has drawn significant attention to the vaccine industry to play a representative role.

Key Points: 
  • As a result, China has drawn significant attention to the vaccine industry to play a representative role.
  • In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
  • Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
  • The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Other Health, General manager, Science, NR, NASDAQ, Sinopharm Group, Securities Act of 1933, Natural health product, TGA, CEO, NHNE, Patent, OTC, NAD, European Commission, Tru, CERP, Year, Health Canada, Company, Marketing, Industry, NMN, Therapeutic Goods Administration, Risk, FSANZ, Growth, Annual report, Research, Security (finance), Multimedia, Brazilian Health Regulatory Agency, History, Watsons, Intention, Ageing, VBP, ANVISA, Drug Quality and Security Act, Sale, Fortune Global 500, SEC, JD, Life, Royal commission, Vitamin D, Â, An Act to exempt a particular class of securities from the Securities and Exchange Act, Food, US, Social media, ChromaDex, Food Standards Agency, COVID-19, China National Pharmaceutical Group

Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.

Key Points: 
  • Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.
  • We are honored to bring such an excellent healthy-aging product to China, said Pan Lei, General Manager of Sinopharm Xingsha.
  • Tru Niagen has also been approved by Health Canada as a Natural Health Product.
  • Sinopharm Xingsha is the health supplement division of Sinopharm Group, a top 100 Chinese nutrition and health consumer brand enterprise, and a key pharmaceutical enterprise in Fujian Province, China.

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

Retrieved on: 
Monday, October 3, 2022
Men, Other Health, General Health, Other Retail, Lifestyle, Specialty, Consumer, Fitness & Nutrition, Retail, Women, Seniors, Vitamins, Supplements, Health, China National Pharmaceutical Group, ChromaDex, NAD, Blue, OTC, NASDAQ, Tru, Human, News, Fortune Global 500, Time, History, Private Securities Litigation Reform Act, Territory, JV, Research, Sinopharm Group, Securities Act of 1933, Industry, VBP, The Act, CEO, Twitter, FDA, Phytochemical, Human body, NR, Ageing, U.S. Securities and Exchange Commission, Science, Prospectus, Sale, Security (finance), Forward-looking statement, Vitamin D, BlueHat, Company, Cryptocurrency

The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.

Key Points: 
  • The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.
  • The private placement was led by existing strategic investors, and included an investment by ChromaDex CEO, Rob Fried.
  • The private placement is expected to close on or about October 7, 2022, subject to the satisfaction of customary closing conditions.
  • The shares of common stock being sold in the private placement will not have been registered under the Securities Act of 1933, as amended (the Act).

Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area

Retrieved on: 
Tuesday, August 30, 2022
Achievement, Investment, Beijing Economic-Technological Development Area, III, Sinopharm Group, Medical device, Fine chemical, Area

NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).

Key Points: 
  • NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).
  • Nanning's investment promotion departments at all levels aim at creatingbiomedical industry clusters through high starting point planning andattraction of targeted investments, according to National Nanning Economic &Technological Development Area Management Committee.
  • In the Area, thebiomedical industry, involving the fields of production, inspection & testing,sales and distribution, continually expands in industrial scale and graduallyimproves in industrial chain.
  • According to information, the Area is the major ground to developthe biopharmaceutical industry in the city, and there are currently 625biopharmaceutical enterprises in the Area.

Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area

Retrieved on: 
Tuesday, August 30, 2022
Achievement, Investment, Beijing Economic-Technological Development Area, III, Sinopharm Group, Medical device, Fine chemical, Area

NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).

Key Points: 
  • NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).
  • Nanning's investment promotion departments at all levels aim at creatingbiomedical industry clusters through high starting point planning andattraction of targeted investments, according to National Nanning Economic &Technological Development Area Management Committee.
  • In the Area, thebiomedical industry, involving the fields of production, inspection & testing,sales and distribution, continually expands in industrial scale and graduallyimproves in industrial chain.
  • According to information, the Area is the major ground to developthe biopharmaceutical industry in the city, and there are currently 625biopharmaceutical enterprises in the Area.

Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area

Retrieved on: 
Tuesday, August 30, 2022
Achievement, Investment, Multimedia, Beijing Economic-Technological Development Area, III, Sinopharm Group, Medical device, Fine chemical, Area

NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).

Key Points: 
  • NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by GuangxiYizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic& Technological Development Area ("Area") has been granted the registrationcertificate of class III medical devices (GXZZ20223210687).
  • Nanning's investment promotion departments at all levels aim at creatingbiomedical industry clusters through high starting point planning andattraction of targeted investments, according to National Nanning Economic &Technological Development Area Management Committee.
  • In the Area, thebiomedical industry, involving the fields of production, inspection & testing,sales and distribution, continually expands in industrial scale and graduallyimproves in industrial chain.
  • According to information, the Area is the major ground to developthe biopharmaceutical industry in the city, and there are currently 625biopharmaceutical enterprises in the Area.

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

Retrieved on: 
Tuesday, October 26, 2021
Sinopharm Group, City, LinkedIn, Hospital, Twitter, Partnership, BLA, Patient, GMP, U.S. Securities and Exchange Commission, Lishui, Shanghai Stock Exchange, Degenerative disease, Forward-looking statement, Company, MM, Lenalidomide, HK, Multiple myeloma, Stock exchange, Population, WeChat, Pharmaceutical industry, Fine chemical

I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China.

Key Points: 
  • I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China.
  • The partnership underscores I-Mab overall vision and lays essential foundation for commercialization in support of its robust pipeline of innovative drug candidates in China.
  • "Since its establishment in 2016, I-Mab has rapidly grown into one of the most promising and innovative biotech companies in China," said Liu Yong, President of Sinopharm.
  • "We are delighted to have entered into the strategic partnership with I-Mab as they prepare for commercialization of its innovative products.

ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China

Retrieved on: 
Wednesday, September 29, 2021
Other Retail, Other Health, Health, General Health, Specialty, Women, Seniors, Men, Retail, Fitness & Nutrition, Consumer, Ministry of Social Affairs, Securities Act of 1933, Partnership, Watsons, Nicotinamide mononucleotide, Risk, Annual report, Drug Quality and Security Act, State, Economy, Ageing, NASDAQ, Therapeutic Goods Administration, Sale, FDA, NR, JD, National Bureau of Asian Research, Central China, TGA, Sinopharm Group, SEC, State-owned Assets Supervision and Administration Commission, Marketing, SASAC, Royal commission, Industry, Company, WeChat, Health Canada, State Council, Tru, Research, National Bureau of Statistics of China, European Commission, NMN, ChromaDex, Securities Exchange Act of 1934, United Nations Department of Economic and Social Affairs, NAD, Pharmaceutical industry

ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (Sinopharm Xingsha) to conduct cross-border sales of Tru Niagen in mainland China.

Key Points: 
  • ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (Sinopharm Xingsha) to conduct cross-border sales of Tru Niagen in mainland China.
  • Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products.
  • Sinopharm Xingsha and ChromaDex will also collaborate to secure Health Food Registration in China.
  • ChromaDex delivers Niagen as the sole active ingredient in its consumer product Tru Niagen available at www.truniagen.com and through partnerships with global retailers and distributors.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Retrieved on: 
Wednesday, September 15, 2021
Insulin, Metformin, NDA, National Medical Products Administration, CEO, Efficiency, Sinopharm Group, Marketing, Diabetes, Ecosystem, Patient, Shanghai Stock Exchange, Company, Type 2, Medicine, GKA, Bayer, T2DM, Homeostasis, Disease, New Drug Application, HK, T2D, Glucokinase, City, Stock exchange, NMPA, News, Type 2 diabetes, Partnership, Hong Kong Stock Exchange, Pharmaceutical industry

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.